主页 > 医学动态 >
【medical-news】期望值过高：B族维生素并不能降低
研究表明，心脏病患者不能通过服用叶酸和其他的B族维生素来降低发病风险。
By Miranda Hitti
WebMD Health News
Aug. 19, 2008 -- If you have heart disease, don't count on folic acid pills, with or without vitamin B6 and B12 supplements, to help you cut your cardiovascular risk.
2008.08.19——如果你患有心脏病，别指望叶酸来降低心血管发病风险，无论是否同时补充维生素B6和B12。
That's according to a new study from Norway published in The Journal of the American Medical Association.
这是依据发表在《美国医疗协会杂志》一篇挪威的新研究而得出的结论。
The study shows that coronary artery disease patients taking cardiovascular drugs didn't cut their risk of death, nonfatal heart attack or clot-related stroke, or other problems by taking folic acid, vitamin B12, and/or vitamin B6 supplements for about three years.
该研究观察服用叶酸、维生素B12和/或维生素B6的冠心病患者三年，结果显示这些药物并未降低他们的死亡率、非致命性心脏病发作率、血栓相关性中风和其他问题发生率。
This isn't the first study to come to that conclusion, and even the Council for Responsible Nutrition, a trade group for the dietary supplement industry, doesn't question the latest findings. But the council argues that the results may not apply to people with healthy hearts.
这样的结论并非首次得出，即使营养负责委员会（一种饮食添加剂工业的商业组织）也未质疑新近的发现。但委员会辩驳这样的结果可能不适用于健康心脏的人。
Heart Disease and B Vitamins
The new study included more than 3,000 heart disease patients in Norway, where folic acid isn't added to wheat as it is in the U.S.
心脏病和维生素B
新研究纳入挪威超过3000例心脏病患者，正如在美国的一样，叶酸没有加入麦片中（并未加入正常饮食中）。
When the study started, the patients were in their early 60s, on average. More than 75% were taking statins, anti-platelet drugs, and beta-blockers to treat their heart disease.
研究开始时，病人年龄平均在60岁出头，超过75％服用statins（一种抗血小板药物）和倍他乐克以控制他们的心脏病。
The patients kept taking those drugs during the study. They were also randomly assigned to either take folic acid plus vitamins B6 and B12, folic acid plus vitamin B12, vitamin B6 alone, or a placebo pill -- without knowing which group they were in.
研究过程中，所有病人持续服用原来的药物，随机分配入四组，分别为服用叶酸外加维生素B6和B12组，叶酸加维生素B12组，维生素B6单用组和安慰剂组，患者并不知道他们被分配在哪组。
During the study, which lasted for just over three years, the patients got periodic blood tests to measure their level of homocysteine, which is an inflammatory chemical linked to higher rates of heart disease.
研究持续超过3年，病人周期查血测定同型半胱氨酸水平，该指标是一种和心脏病高发病率相关的炎症化学因子。
The researchers expected homocysteine levels to drop in the folic acid groups. The key question was what difference that would make to the patients' heart health. The short answer: Homocysteine levels fell as predicted, but it didn't matter much.
研究者期望叶酸组患者的同型半胱氨酸水平下降，关键问题是这在患者心脏疾病的有什么作用，简单的回答是：其水平确实按预期的下降，但这无关紧要。
No Support for B Vitamins
Over the course of the trial, the patients taking folic acid and vitamin B12 had the biggest drop in their homocysteine level, which wound up 26% lower than patients who weren't taking folic acid.
不支持维生素B族
研究过程中，叶酸加维生素B12组的患者同型半胱氨酸水平下降最大，较未服用叶酸组患者降低26％。
But even those patients weren't less likely to die of any cause, suffer a nonfatal heart attack or clot-related stroke, be hospitalized due to unstable angina (chest pain), or need to have a narrowed or blocked coronary artery surgically reopened.
但那些病人因各种原因死亡的可能性没有变小。这些原因包括患非致命性心脏病发作，或血栓相关性中风，因不稳定心绞痛（胸痛）而住院，或让狭窄、阻塞的冠脉外科再通。
Those "events" happened to similar percentages of patients -- ranging from 12% to 16% -- in each group. The differences in those percentages were so small that they may have been due to chance.
这些事件在各组之间有相似的发病率，从12％到16％。这些百分比如此相近，可以认为是随机因素所致（而无统计学意义）。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-15 05:14
医学,生命科学网